101 related articles for article (PubMed ID: 9103485)
1. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.
Kaplan HL; Busto UE; Baylon GJ; Cheung SW; Otton SV; Somer G; Sellers EM
J Pharmacol Exp Ther; 1997 Apr; 281(1):103-8. PubMed ID: 9103485
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.
Tomkins DM; Otton SV; Joharchi N; Li NY; Balster RF; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Mar; 280(3):1374-82. PubMed ID: 9067326
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.
Otton SV; Schadel M; Cheung SW; Kaplan HL; Busto UE; Sellers EM
Clin Pharmacol Ther; 1993 Nov; 54(5):463-72. PubMed ID: 7693389
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys.
Lelas S; Wegert S; Otton SV; Sellers EM; France CP
Drug Alcohol Depend; 1999 May; 54(3):239-49. PubMed ID: 10372797
[TBL] [Abstract][Full Text] [Related]
7. Effect of metabolic blockade on the psychoactive effects of dextromethorphan.
Zawertailo LA; Tyndale RF; Busto U; Sellers EM
Hum Psychopharmacol; 2010 Jan; 25(1):71-9. PubMed ID: 20041473
[TBL] [Abstract][Full Text] [Related]
8. Hydrocodone in postoperative personalized pain management: pro-drug or drug?
Stauble ME; Moore AW; Langman LJ; Boswell MV; Baumgartner R; McGee S; Metry J; Jortani SA
Clin Chim Acta; 2014 Feb; 429():26-9. PubMed ID: 24269714
[TBL] [Abstract][Full Text] [Related]
9. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
10. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
Zacny JP; Gutierrez S
Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.
Kathiramalainathan K; Kaplan HL; Romach MK; Busto UE; Li NY; Säwe J; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 2000 Aug; 20(4):435-44. PubMed ID: 10917405
[TBL] [Abstract][Full Text] [Related]
13. Observations on the urine metabolic profile of codeine in pain patients.
Yee DA; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Mar; 38(2):86-91. PubMed ID: 24396053
[TBL] [Abstract][Full Text] [Related]
14. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
Susce MT; Murray-Carmichael E; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
[TBL] [Abstract][Full Text] [Related]
15. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
Zawertailo LA; Kaplan HL; Busto UE; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 1998 Aug; 18(4):332-7. PubMed ID: 9690700
[TBL] [Abstract][Full Text] [Related]
16. Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing.
Busto UE; Zawertailo LA; Kaplan HL; Sellers EM
Can J Clin Pharmacol; 1999; 6(2):103-10. PubMed ID: 10519736
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of hydromorphone, hydrocodone and their 6alpha- and 6beta-hydroxy metabolites in urine using selected ion recording with methane chemical ionization.
Cone EJ; Darwin WD
Biomed Mass Spectrom; 1978 Apr; 5(4):291. PubMed ID: 76483
[TBL] [Abstract][Full Text] [Related]
19. CYP2D in the brain impacts oral hydrocodone analgesia in vivo.
Richards J; Miksys S; Novalen M; Tyndale RF
Neuropharmacology; 2022 Dec; 221():109291. PubMed ID: 36241086
[TBL] [Abstract][Full Text] [Related]
20. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
Madadi P; Hildebrandt D; Gong IY; Schwarz UI; Ciszkowski C; Ross CJ; Sistonen J; Carleton BC; Hayden MR; Lauwers AE; Koren G
Pediatrics; 2010 Oct; 126(4):e986-9. PubMed ID: 20837591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
